ANDA 76671, held by Pharmobedient. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 76671 (Sertraline Hydrochloride), held by Pharmobedient, was first approved by FDA on Feb 6, 2007, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 6, 2007 | Original application | Approved | None posted |
| Sertraline HydrochlorideEQ 25MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Sertraline HydrochlorideEQ 50MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Sertraline HydrochlorideEQ 100MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Feb 5, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 5, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Dec 13, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Dec 21, 2012 | Supplement 11Labeling | Approved | None posted |
| Jun 25, 2010 | Supplement 8Labeling | Approved | None posted |
| Jun 25, 2009 | Supplement 6Labeling | Approved | None posted |
| Jan 6, 2009 | Supplement 5Labeling | Approved | None posted |
| Jul 16, 2008 | Supplement 4Labeling | Approved | None posted |
| Jan 9, 2008 | Supplement 2Labeling | Approved | None posted |
| Jan 9, 2008 | Supplement 3Labeling | Approved | None posted |
| Feb 6, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters